Errors in insulin treatment management and risk of lipohypertrophy
- 2 November 2017
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 55 (1) , 67-73
Abstract
Lipohypertrophy (LH) represents the most common skin-related complication associated with insulin therapy. Our aim is to estimate the prevalence of LH among insulin-treated patients, to identify its association with errors in insulin injection technique and storage, and the correlation between LH, risk of hypoglycemia, and glycemic control.Keywords
This publication has 16 references indexed in Scilit:
- New Insulin Delivery RecommendationsMayo Clinic Proceedings, 2016
- Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?Diabetes Therapy, 2016
- Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose ControlDiabetes Care, 2016
- Improvement of Insulin Injection TechniqueThe Diabetes Educator, 2016
- A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetesSpringerPlus, 2016
- Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetesDiabetes & Metabolism, 2013
- Results and analysis of the 2008–2009 Insulin Injection Technique Questionnaire surveyJournal of Diabetes, 2010
- Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literatureExpert Opinion on Drug Safety, 2009
- Incidence of lipohypertrophy in diabetic patients and a study of influencing factorsDiabetes Research and Clinical Practice, 2007
- Impaired Absorption of Insulin Aspart From Lipohypertrophic Injection SitesDiabetes Care, 2005